Medicalsystem Biotechnology300439.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Medicalsystem Biotechnology (300439.SZ) trades at a P/E of 55.00x, P/B of 1.26x, P/S of 2.27x, and a dividend yield of 0.34%.
Longitudinal percentile comparison: P/E sits at the 92nd percentile over the trailing 10Y window (vs. 85th percentile over 3Y); P/B sits at the 8th percentile over the trailing 10Y window (vs. 26th percentile over 3Y); P/S sits at the 41st percentile over the trailing 10Y window (vs. 42nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 63rd percentile within its industry and the 64th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.34%, ranking at the 33rd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 84.2 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Medicalsystem Biotechnology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300439 · SZSE: 300439 · 300439
Want the full picture on whether Medicalsystem Biotechnology (300439.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 55.00 | ||||||
| P/B (MRQ) | 1.26 | ||||||
| P/S (TTM) | 2.27 | ||||||
| Dividend Yield | 0.34% | ||||||
| Buyback + Div Yield | 0.34% |